Insider Buying: Vivani Medical (NASDAQ:VANI) Director Purchases $1,981,052.10 in Stock

Vivani Medical, Inc. (NASDAQ:VANI) Director Gregg Williams purchased 1,737,765 shares of the firm’s stock in a transaction on Thursday, January 15th. The shares were purchased at an average price of $1.14 per share, for a total transaction of $1,981,052.10. Following the completion of the purchase, the director directly owned 26,564,109 shares of the company’s stock, valued at $30,283,084.26. This represents a 7.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.

Gregg Williams also recently made the following trade(s):

• On Monday, December 15th, Gregg Williams acquired 1,737,765 shares of Vivani Medical stock. The stock was purchased at an average price of $1.14 per share, for a total transaction of $1,981,052.10.
• On Saturday, November 15th, Gregg Williams bought 1,737,764 shares of Vivani Medical stock. The shares were purchased at an average cost of $1.14 per share, for a total transaction of $1,981,050.96.
• On Monday, October 27th, Gregg Williams bought 3,703,703 shares of Vivani Medical stock. The shares were purchased at an average price of $1.62 per share, with a total value of $5,999,998.86.

Vivani Medical Price Performance

NASDAQ VANI opened at $1.47 on Friday. The company has a market cap of $107.24 million, a P/E ratio of -3.27 and a beta of 3.07. The stock has a 50-day moving average of $1.35 and a two-hundred day moving average of $1.39. Vivani Medical, Inc. has a 1-year low of $0.91 and a 1-year high of $1.92.

Vivani Medical (NASDAQ:VANI) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.01. On average, analysts anticipate that Vivani Medical, Inc. will post -0.41 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Vivani Medical in a research note on Friday, January 9th. Zacks Research upgraded Vivani Medical from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 12th. Finally, Wall Street Zen upgraded Vivani Medical to a “sell” rating in a research note on Saturday, November 22nd. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Vivani Medical currently has a consensus rating of “Hold” and an average price target of $4.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Panagora Asset Management Inc. acquired a new position in Vivani Medical in the second quarter valued at approximately $25,000. Susquehanna International Group LLP lifted its position in shares of Vivani Medical by 100.5% during the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock worth $46,000 after buying an additional 16,200 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new position in shares of Vivani Medical in the 3rd quarter valued at $26,000. 6.78% of the stock is owned by institutional investors and hedge funds.

About Vivani Medical

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.